Abstract 565P
Background
Acquired genomic alternations are known mechanisms of resistance to osimertinib in patients with advanced epidermal growth factor receptor (EGFR) positive non-small cell lung cancer (NSCLC). Addition of genome-guided targeted therapy (GGTT) to osimertinib may improve treatment outcomes.
Methods
This retrospective study reviewed 226 metastatic EGFR mutation positive NSCLC patients who received systemic therapy after failing osimertinib. Primary endpoints include time-to-treatment failure (TTF) and overall survival (OS) from post-osimertinib failure.
Results
Total of 68 patients had genomic analysis for osimertinib resistance and 21 (30%) had targetable genomic alternations. Out of which, 17 received osimertinib plus GGTT (13 MET amplification, 2 ALK rearrangement, 1 RET rearrangement and 1 BRAF V600E mutation) and 209 patients received chemotherapy. Median follow-up were 10.0 and 30.1 months for GGTT and chemotherapy group respectively. The GGTT group achieved significantly longer TTF (not reached [NR] vs 5.1 months, HR 0.19, 95% CI 0.08-0.48, p<0.001) and OS (NR versus 10.5 months, HR 0.27, 95% CI 0.09-0.86, p=0.026) compared to those receiving chemotherapy. These results remained significant after multivariate analysis (Table). In subgroup analysis, TTF of GGTT group was superior to chemotherapy alone (n=148) (NR versus 4.5 months, HR 0.18, p<0.001), chemotherapy plus osimertinib (n=41) (NR versus 6.2 months, HR 0.23, p=0.003) and chemotherapy plus anti-PD(L)1 plus anti-VEGF (n=20) (NR versus 6.3 months, HR 0.25, p=0.009), respectively. Table: 565P
Time to treatment failure | Overall survival | |||||||
Univariate | Multivariate | Univariate | Multivariate | |||||
HR | P-value | HR | P-value | HR | P-value | HR | P-value | |
Age (>65) | 0.95 | 0.74 | 1.16 | 0.35 | ||||
Gender (Female) | 0.94 | 0.43 | 0.85 | 0.046 | ||||
PS (>1) | 1.67 | 0.014 | 1.75 | 0.009 | 2.54 | <0.001 | 2.73 | <0.001 |
EGFR (ex19 del vs L858R)* | 1.03 | 0.83 | 0.98 | 0.91 | ||||
Line of Osimertinib (>1) | 1.51 | 0.037 | 1.40 | 0.10 | ||||
CNS metastases | 1.09 | 0.55 | 1.28 | 0.12 | ||||
Liver metastases | 1.30 | 0.05 | 1.36 | 0.05 | 1.42 | 0.037 | 1.50 | 0.016 |
Bone metastases | 1.92 | 0.001 | 1.71 | 0.011 | ||||
Therapy (GGTT) | 0.19 | <0.001 | 0.22 | 0.001 | 0.27 | 0.026 | 0.24 | 0.015 |
∗2 patients with EGFR mutations other than exon 19 deletion and exon 21 L858R mutation excluded from analysisCNS, central nervous system; EGFR, epidermal growth factor receptor; PS, performance status
Conclusions
The combination of GGTT and osimertinib improves TTF and OS in EGFR mutation positive NSCLC patients failing osimertinib. Future prospective comparative study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.S.C. Li: Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Takeda, Pfizer, Guardant Health; Financial Interests, Personal, Research Grant: Gilead, Takeda; Financial Interests, Personal, Invited Speaker: BMS, Amgen, ACE Oncology, AstraZeneca, Novartis, Takeda. K.W.C. Lee: Financial Interests, Personal, Full or part-time Employment: ACT Genomics; Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Takeda, Janssen, C-stone; Financial Interests, Personal, Advisory Board: Merck, Janssen, Novartis; Financial Interests, Personal, Stocks or ownership: ACT Genomics, Prenetics. H.H.F. Loong: Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Eli Lilly, Illumina, Bayer, Guardant Health; Financial Interests, Personal, Advisory Board: Novartis, Takeda. T.S.K. Mok: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, Berry Oncology, Boehringer Ingelheim, C4 Therapeutics, D3 Bio, Eisai, G1 Therapeutics, Gritstone Oncology, GeneDecode, Hutchmed, Incyte Corporation, IQVIA, Lilly, Lunit, MSD, Novartis, Puma Biotechnology, Roche, SFJ Pharmaceuticals, Vertex Pharmaceuticals, Yuhan Corporation, ACEA Pharma, AstraZeneca, Blueprint, BMS, Covidien LP, Curio Science, Daiichi Sankyo, Fishawack Facilitate, Gilead Sciences, Guardant Health, Hengrui, Ignyta, Inivata, Janssen, Loxo Oncology, Merck Serono, Mirati, Origimed, Pfizer, Sanofi Aventis, Takeda, Virtus; Financial Interests, Personal, Research Grant: AstraZeneca, BMS, Pfizer, Roche, Novartis, SFJ Pharmaceuticals, MSD, G1 Therapeutics, Takeda, XCovery, Merck Serono; Financial Interests, Personal, Invited Speaker: ACEA Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fishawack Facilitate, Janssen, Lucence Health, Medscape LLC, MSD, OrigiMed, PeerVoice, Pfizer, Research to Practice, Sanofi-Aventis, Liangyihui Network Technology, Takeda, Alpha Biopharma, Amoy Diagnostics, BeiGene, BMS, Daz Group, InMed Medical Communication, Lilly, MD Health Brazil, Merck, Novartis, P. Permanyer, Physicians' Education Resource, PrIME Oncology, Roche, Shanghai BeBirds, Taiho, Touch Independent Medical Education; Financial Interests, Personal, Leadership Role: AstraZeneca, Lunit, ATORG, CSCO, HKCTS, HutchMed, ASCO, CLCRF, HKCF; Financial Interests, Personal, Stocks or ownership: Aurora Tele-Oncology, Hutchmed, ACT Genomic. All other authors have declared no conflicts of interest.
Resources from the same session
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract